Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Chaccour
 
NCT04390022
RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
12/12 inconclusive
  • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

COVID 19 outpatients meta-analysis

ACTIV-6 (ivermectine)
 
NCT04885530
RCTivermectinplaceboCOVID 19 outpatientslow
602/604 inconclusive
    ACTIV 6 ivermectin
     
    NCT04885530
    RCTivermectinplaceboCOVID 19 outpatientslow
    817/774 inconclusive
      COVID-OUT (ivermectin)
       
      NCT04510194
      RCTivermectinplaceboCOVID 19 outpatientssome concern
      410/398 inconclusive
        TOGETHER (ivermectine)
         
        NCT04727424
        RCTivermectinplaceboCOVID 19 outpatientslow
        679/679 inconclusive
        • inconclusive 10 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
        Lopez-Medina
         
        NCT04405843
        RCTivermectinplaceboCOVID 19 outpatientssome concern
        200/200 inconclusive
        • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        IVERCORCOVID19 (Vallejos)
         
        NCT04529525
        RCTivermectinplaceboCOVID 19 outpatientslow
        250/251 inconclusive
        • inconclusive 35 % decrease in hospitalization (PE) with a high degree of certainty due to low risk of bias

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).